Hilly Paige Shares Key Takeaways from 2025 ESC/EAS Cholesterol Guideline
Hilly Paige, Chief Innovation Officer at the Family Heart Foundation, has shared a post on LinkedIn:
“Great overview by Family Heart Foundation of the new cholesterol guidelines from European Society of Cardiology and European Atherosclerosis Society.
Figure 2 from the 2025 update is superb. Combinations of proven therapies can lower LDL-C by up to 86%! With so many safe and effective therapies available in the toolbox, it is unacceptable that currently <30% of high-risk individuals are achieving their LDL-C goals!
Also, great to see two important LDL-C lowering therapies included in the 2025 update – bempedoic acid from Esperion and evinacumab from Regeneron!
Finally, using supplements to lower your LDL-C? Don’t waste your money.”
Check here for more information.
Stay informed with Hemostasis Today.
-
Aug 11, 2026, 11:47Rucha Patil: Strengthening Evidence-Based Haemophilia Care Across India
-
Aug 11, 2026, 11:38Maria Hadjidemetriou: The Patient Perspective in Thalassemia Care
-
Aug 11, 2026, 11:04Wolfgang Miesbach: The Critical Need for Tailored Dosing in VWD
-
Aug 11, 2026, 08:20Hasan Abbas Zaheer: Strengthening Universal Access to Safe Blood in Pakistan
-
Aug 11, 2026, 08:07Nicola Pozzi: Advancing Hemostasis Through Scientific Collaboration at Hemostasis GRC
-
Aug 11, 2026, 07:50When Access to Care Changes Everything – WFH
-
Aug 11, 2026, 07:41Kevin Land: How Cellular Therapy Is Changing Transfusion Medicine
-
Aug 11, 2026, 07:35Kuldeep Singh Bhadauria: Building the Future of Hemophilia Care in India
-
Aug 11, 2026, 07:28Archil Jaliashvili: When Every Minute Matters Time Becomes a Therapy